The effects of intravenous administration of glucagon (50 ,ug/kg) on left coronary blood flow and myocardial oxygen consumption were studied in nine patients during diagnostic cardiac catheterization and in six open-chested anesthetized dogs. Coronary blood flow was measured with the '33Xe washout technic in man, and with an electromagnetic flowmeter placed around the left anterior descending coronary artery in the dogs. In the patients, glucagon produced a 31% increase in coronary blood flow and a 29% increase in myocardial oxygen consumption, with no change in coronary arteriovenous (A-V) 02 difference across the heart. In the dogs glucagon produced a 114% increase in coronary blood flow and a 131% increase in myocardial oxygen consumption, again with no change in coronary A-V 02 difference. Thus glucagon is a secondary coronary vasodilator in both man and dog. The modest chronotropic and inotropic effects of glucagon observed in man were only half as great as those observed in the dog. Part or all of this difference in dose-response relationship between the two species may be related to the different experimental conditions of the study.
T HE CARDIOTONIC actions of glucagon, a 29-amino acid polypeptide hormone, have been demonstrated in various animal preparationsl-5 and in humans during cardiac catheterization"9 and in the postoperative period following prosthetic valve replacement.10 In patients with chronic congestive heart failure equivocally beneficial effects have been noted. [11] [12] Glucagon has a positive inotropic and a This study was supported in part by Grants 11306-03, RO1-HE-8591-05, and ITI-5679-04 from the U. S. moderate chronotropic effect which are manifest as an increase in the maximum rate of ventricular pressure development (Ap/At) and cardiac output, accompanied by a small increase in heart rate, an augmentation of atrioventricular conduction, and a reduction in systemic vascular resistance.4' 5 13, 14 The inotropic effects of glucagon are unusual in that they occur in the absence of catecholamines or in the presence of 38adrenergic blockade and may be superimposed on full digitalization without incurring arrhythmias.4-6, 10 Despite the recent intensive study of the cardiovascular effects of glucagon, no dat.a are available concerning its effects on myocardial oxygen consumption and coronary blood flow.
In view of the potential usefulness of this hormone in the presence of acute cardiac insufficiency the present study was designed to analyze these important factors.
Methods

Human Subjects
Eight men and one woman were studied during diagnostic cardiac catheterization. Six of the subjects had atherosclerotic coronary artery disease, one had mitral stenosis and normal coronary arteriography, and two had a chest pain syndrome with normal coronary arteriography. The patients' ages ranged from 30 to 53 years, with a mean age of 43.5 years. As judged by hemodynamic data, cardiac failure was absent. Clinical data are given in table 1. Patients were studied in the fasting state following premedication with meperidine, 50 mg, and pentobarbital sodium, 100 mg, administered intramuscularly 45 min prior to the cardiac catheterization.
A polyethylene catheter was placed in the left brachial artery by the Seldinger technic. A Sones catheter was passed through a cutdown on the right brachial artery and advanced into the left ventricle for the study period. A Goodale-Lubin catheter was passed through an antecubital vein and placed in the lateral coronary sinus. Blood sampled from this site was assumed to be representative of blood from the left ventricular myocardium. The position of the coronary sinus catheter was maintained constant throughout the study. Selective coronary cinearteriography was performed in multiple projections by the technic of Sones and Shirey,15 employing 75% sodium and megluamine diatrizoate. Atherosclerotic coro-nary artery disease was defined as angiographic evidence of any coronary arterial intraluminal narrowing or irregularity, or both. Pressures were measured with Statham P23Db strain gauges and recorded on a Sanbom 560 polybeam photographic recorder. Cardiac output was measured by the indicator-dilution technic with indocyanine-green dye and a Gilford densitometer. Green dye was injected into the right atrium, and arterial blood was sampled from the brachial artery catheter. Coronary flow was measured by the method of Ross and associates,16 with selective left coronary injection of '33Xe through a no. 7 or 8 Sones catheter, the disappearance of the gas from the myocardium being measured with a precordial counter. The time activity curve was recorded with a Picker ratemeter operating with a 0.3-sec time constant and a recorded paper speed of 3 inches/min. Flows were calculated, as described by Klein and associates,'7 by determining the rate constant from the semilog replot of the washout curves. As the washout curve is not monoexponential, the terminal portion of the precordial washout curve (slow component) was extrapolated to the zero time intercept anl subtracted from the original curve. The resultant fast component of flow was used for the calculation of coronary blood flow. Blood oxygen content and capacities were determined in duplicate by the method of Van Slyke and Neill.18 Systolic ejection period and systolic and diastolic mean pressures were measured from brachial arterial pressure pulses. Myocardial oxygen consumption per 100 g of left ventricle was calculated as the product of coronary flow and myocardial arteriovenous oxygen difference (ml/liter). Coronary and systemic vascular resistances were calculated.'9 Left ventricular function was assessed in terms of 18 to 25 kg, were anesthetized with pentobarbital sodium, intubated, and maintained on a Harvard respirator. A bilateral transsternal incision in the fifth intercostal space afforded adequate cardiac exposure. One of the internal mammary or carotid arteries was cannulated with a Silon catheter for measurement of peripheral arterial pressure. A 16 to 18-mm electromagnetic flow probe was placed around the ascending aorta to record aortic flow. A 3 to 4-mm electromagnetic flow probe was placed around the left anterior descending coronary artery in six dogs to record coronary flow. A polyethylene catheter was placed in the anterior coronary sinus through an atrial-purse string suture. A short 8-F catheter was placed in the left ventricle through an apical purse-string suture for the measurement of left ventricular pressure. Teflon-coated pacing electrodes were placed in the right ventricular myocardium. Permanent heart block was induced in all six dogs by transatrial infiltration of the A-V node with 40% formaldehyde2l and the heart was paced at a constant rate about 150 beats/min. The electrocardiogram, peripheral arterial pressure, left ventricular pressure, maximum rate of left ventricular pressure development (Ap/At), central aortic flow, and left anterior descending coronary artery flow were recorded on an 8channel Lexington oscilloscope-recorder. Stroke volume was obtained as the electrical integral of central aortic flow. Maximum LV Ap/At was electrically differentiated from the left ventricular pressure tracing. Blood oxygen content and capacities were determined in duplicate by the method of Van Slyke and Neill. Measurements were made at rest at a time when pressure and flow had been stable for at least 3 min and a few minutes after a 2 to 3-min intravenous infusion of glucagon (50 ,ug/kg) in normal saline.
Circudation, Volume XLI, Apri 1970 All statistical comparisons were performed with Student's paired t-test.
Results
Hemodynamic Effects
The onset of action of glucagon was evident in 3 min following intravenous administration, as noted by an increase in heart rate and arterial pulse pressure. A maximum effect was attained in 5 to 7 min, and lasted approximately 15 min. Transient nausea occurred in five patients. In these subjects no observations were made until heart rate and pressure were stable for at least 2 min following the nausea. No arrhythmias were seen in association with the administration of glucagon.
The hemodynamic effects of glucagon observed in this study are presented in table 2. The mean values for the patient and dog studies are listed, while percentage changes for the individual experiments are presented as the mean + SEM. Statistical significance was evaluated by the paired t-test.
In the patients studied, glucagon produced a modest increase in heart rate ( 11 + 4%), cardiac index (22 ± 13%), and arterial pressure (6 + 2%) with no change in LVEDP, and a slight fall in systemic vascular resistance (-11+4%). The increase in contractile state was manifested by an increase in left ventricular Ap/At (26 + 12%) and systolic ejection rate (28 + 13%). As indices of an increase in ventricular work, there were increases in both pressure time per minute (11 + 4%) and left ventricular work (29 + 6%).
Infusion of glucagon into dogs (table 2) produced directionally similar changes, but of a greater magnitude than those seen in man. A relative comparison of the hemodynamic effects of the same dose of glucagon per unitweight (50 /Lg/kg) in man and dog is shown in figure 1 . Thus, in the specific circumstances under which these two species were studied, the hemodynamic effects of glucagon were at least twice as great in the dog as in man.
Effects on Coronary Flow Figure 2 shows typical precordial scintigrams after selective injection of 133xenon into the left coronary artery before and after the infusion of glucagon. Calculation of the myocardial clearance rate is illustrated. The increase in myocardial clearance is obvious from the precordial curves and the semilog replot of the fast component of the washout curves. The subject, a 38-year-old man with atherosclerotic disease in two coronary arteries, had an increase in coronary flow from 73 to 118 ml/min/ 100 g of left ventricle. The combined results of such studies in both species are presented in table 3. In man glucagon produced a modest increase in coronary blood flow (31 + 10%) and myocardial oxygen consumption (29 + 13%) with no change in coronary A-V 02 difference, or 02 extraction ratio. A moderate decrease in coronary vascular resistance (-20 8%) ac-Circulation, Volume XLI, April 1970 companied this increase in coronary blood flow.
Again directionally similar but larger changes were seen in the dogs studied (table  3) as further illustrated in figure 3 by a direct comparison of the percentage changes observed. The marked difference between the two species in the magnitude of the increased coronary flow and myocardial oxygen consumption is evident, under somewhat different experimental conditions. Metabolic alterations secondary to glucagon in man are shown in table 4. Blood glucose increased by an average of 69 + 11 mg % (P <0.05) whereas serum potassium concentration fell from an average of 4.1 to 3.9 mEq/L (-10 ± 2%; P < 0.05). Transmyocardial lactate extraction occurred at rest in eight of the nine subjects. With glucagon infusion, transmyocardial lactate production was reversed to extraction in one subject with anaerobiosis at rest, and persistent lactate extraction was noted in the eight subjects with extraction at rest.
Discussion
Recent studies have shown glucagon to have a direct positive inotropic action'-10 on the heart despite cardiac catecholamine depletion, blockade of f3-adrenergic receptors,4-5 or the presence of full digitalization.4 6, 10 Furthermore, glucagon has a moderate chronotropic effect,4' 5 and increases atrioventricular conduction with little or no arrhythmagenic activity.13' 14 Accordingly, it has been suggested that glucagon may be beneficial in the presence of depressed cardiac function as in postoperative low output states, cardiogenic shock, acute congestive heart failure, or in the presence of 8-adrenergic blocking agents.
Since the oxygen consumption of the heart is largely determined by heart rate, arterial pressure, and contractility,22 all of which were increased to some degree by glucagon, an increase in myocardial oxygen consumption would be anticipated and has been observed. Since the extraction of oxygen from arterial coronary blood is nearly complete, any increase in oxygen consumption is generally The left panels show the washout of 133Xe from the myocardium before and a few minutes after the intravenous injection of glucagon (50 pg/kg). 133Xe was selectively injected into the left coronary artery of this patient, and the curves were obtained from a precordial counter placed over the apex of the left ventricle. The data have been replotted on a log scale in the right panels and separated into a fast and slow component by the curve-peeling method. The t30 was measured from the fast component for the calculation of coronary flow. associated with a decrease in coronary vascular resistance and an appropriate increase in flow, as was noted following glucagon administration. To be considered a vasodilator, an agent must produce an increase in coronary flow out of proportion to a rise in perfusing pressure. 23 Such was the case here, since coronary flow rose substantially more than did diastolic perfusion pressure, and calculated coronary vascular resistance significantly decreased. However, vasodilation may be primary or secondary to the increased oxygen requirements of the heart. Vasodilation is considered to be primary if the arteriovenous oxygen difference across a vascular bed narrows, indicating that the flow rose more than energy demand, and secondary if arterio-venous oxygen difference remains constant.24
In the present study, coronary arteriovenous oxygen difference, coronary venous oxygen saturation, and per cent extraction of oxygen by the myocardium did not change significantly, despite significant increases in coronary blood flow and myocardial oxygen consumption. Thus, glucagon may be considered to be a secondary vasodilator in both intact man and open-chested anesthetized dogs. This is similar to the effect of epinephrine25 and different from the primary vasodilating action of isoproterenol26 on the coronary circulation.
Normally the myocardium functions on an aerobic basis with virtually no anaerobic glycolysis occurring in the heart at rest or under stress.27 This can be measured by the persistent extraction of lactate by the portion of myocardium sampled. In the present study the persistent transmyocardial lactate extraction before and after glucagon infusion revealed no apparent anaerobic metabolism. This finding confirms the oxygen data and suggests that the augmentation of coronary flow was sufficient to meet the increased energy requirements of the heart following glucagon.
The observed hemodynamic actions of glucagon were similar to those already noted.6-9 In man, glucagon produced a slight increase in heart rate, a slight decrease in peripheral vascular resistance, and a moderate increase in cardiac contractility. In the animals glucagon effected a marked increase in contractile state and a moderate decrease in peripheral vascular resistance. The increased contractile state was manifested by increases in mean systolic ejection rate, average Ap/At, The major determinants of myocardial oxygen consumption are intramyocardial tension, heart rate, and the contractile state of the heart.22 Tension in the wall of the ventricle is a direct function of the intraventricular radius and pressure and an inverse function of the ventricular wall thickness. Heart rate determines the number of times per minute the heart is activated and, thus, the cumulative tension that is developed.
Since LVEDP, which reflects left ventricular end-diastolic volume, was not changed by glucagon in man, one may assume that there was a modest increase in tension-time per minute. In the animals with constant heart rate, a smaller increase in tension-time per minute occurred since a 50% reduction in enddiastolic pressure occurred. Thus, in the dog the rise in myocardial oxygen consumption appears to be in excess of the increase in tension-time per minute. This suggests that another factor, increased contractility, must be responsible for the large increases in myocardial oxygen consumption, as reflected in the increased mean systolic ejection rate, and LV Ap/At. Thus, one may conclude that the increase in contractile state induced by glucagon may lead to a substantial increase in oxygen consumption.
In both species the increased oxygen consumption of the heart (table 3) was similar in magnitude to the calculated increase in left ventricular work (table 2) . Thus, it would appear that glucagon had no measurable uncoupling or oxygen-wasting effect.
The greater hemodynamic response to glucagon in dogs observed in this study might be due either to a species difference in doseresponse relationships or to the different experimental conditions of the study. Support for the latter view is gained from the recent observations of Lucchesi and associates14 that the awake, unanesthetized dog has little or no chronotropic response to glucagon as compared to the anesthetized dog. Certainly the degree of cardiac depression present in the anesthetized dog would allow for a greater inotropic response because the heart is far below its ceiling of contractility.
These studies lend support to the view that glucagon is a potentially useful inotropic agent which may supplement glycosides or catecholamines under the proper circumstances since its mode of action is independent of these agents or their receptors. Like all agents which increase contractility, it too augments oxygen consumption of the heart. While the usefulness of glucagon has been suggested in cardiogenic shock,28 the associated increase in oxygen consumption must still be considered. Clinical research and the toilsome discoveries of new technical methods are as fully entitled to the term "scientific" as any of the good work done in our laboratories. The complexities of clinical research are so intricate, and because of the human material upon which they are conducted are so bewildering as perhaps to surpass all forms of laboratory research in difficulty. They call for qualities of insight, imagination, patience, and intellectual integrity to a no less considerable degree. The practice of clinical medicine or surgery makes a further heavy demand upon qualities of temperament and of character which are little exercised in the clistered tranquillity of the laboratory. Yet the rewards open to the clinical investigator by the only scientific body competent to give them, the Royal Society, are consistently withheld. The present President of the Royal Society is a medical man whose life has been spent in the laboratory, with the result that physiology and general medicine have been permanently and very greatly enriched by his labours. But there are physicians and surgeons whose lives have been spent in the wards and in the operation theatres of our hospitals whose contributions to "scientific" medicine are entitled to rank even with his. The joint and separate labours of the laboratory worker and of the clinician are both, perhaps equally, necessary for the future progress of medicine in all its branches. Both are deserving of recognition at the hands of those empowered to confer it; in "scientific" value one does not surpass the other.-From MOYNIHAN, BERKELEY: Letter to the Editor. The Times, London, July 27, 1923.
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